Department of Ophthalmology, Meir Medical Center, Kfar Saba, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Curr Pharm Des. 2018;24(41):4860-4863. doi: 10.2174/1381612825666190123165216.
Exudative age-related macular degeneration (AMD) is a major indication for the administration of intravitreal injections of anti-VEGF agents, which have been established as a very effective pharmacotherapy for this disease. However, treatment with anti-VEGF agents requires several patient visits for monitoring and treatment. Strategies for achieving a longer duration of pharmacological action are currently being developed. These include the development of longer-acting drugs, and of novel technologies to increase the duration of action of administered agents. This manuscript will review the novel drugs and technologies currently being developed for achieving a longer-action pharmacotherapy for exudative AMD.
渗出型年龄相关性黄斑变性（AMD）是眼内注射抗血管内皮生长因子（VEGF）药物的主要适应证，抗 VEGF 药物已被确立为治疗该病的一种非常有效的药物疗法。然而，抗 VEGF 药物治疗需要多次就诊以进行监测和治疗。目前正在开发能够延长药物作用时间的策略。这些策略包括开发作用时间更长的药物，以及开发新技术以增加给予药物的作用时间。本文将综述目前正在开发的用于实现渗出型 AMD 更长效药物治疗的新型药物和技术。
